3109
T3D3067
Vapreotide
Vapreotide is only found in individuals that have used or taken this drug. It is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.The exact mechanism of action is unknown, although one study has provided in vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect in the analgesic effects of vapreotide (A2442).
103222-11-3
23725064
C57H70N12O9S2
1130.483010
White powder.
3.99e-03 g/L
The exact mechanism of action is unknown, although one study has provided in vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect in the analgesic effects of vapreotide (A2442).
Route of Elimination: Vapreotide is 76% eliminated in bile. The remainder is renally eliminated.
Half Life: 30 minutes
No indication of carcinogenicity to humans (not listed by IARC).
For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.
Safety data are limited, however, headache, fatigue, diarrhea, nausea, vomiting, and abdominal pain have been reported commonly with the use of vapreotide.
2009-07-21T20:29:00Z
2014-12-24T20:25:56Z
Vapreotide
DB04894
true
CC(C)C1N=C(O)C(CCCCN)N=C(O)C(CC2=CNC3=CC=CC=C23)N=C(O)C(CC2=CC=C(O)C=C2)N=C(O)C(CSSCC(N=C1O)C(O)=NC(CC1=CC2=CC=CC=C2N1)C(O)=N)N=C(O)C(N)CC1=CC=CC=C1
C57H70N12O9S2
InChI=1/C57H70N12O9S2/c1-32(2)49-57(78)68-48(55(76)64-44(50(60)71)28-37-26-35-14-6-8-16-41(35)62-37)31-80-79-30-47(67-51(72)40(59)24-33-12-4-3-5-13-33)56(77)65-45(25-34-19-21-38(70)22-20-34)53(74)66-46(27-36-29-61-42-17-9-7-15-39(36)42)54(75)63-43(52(73)69-49)18-10-11-23-58/h3-9,12-17,19-22,26,29,32,40,43-49,61-62,70H,10-11,18,23-25,27-28,30-31,58-59H2,1-2H3,(H2,60,71)(H,63,75)(H,64,76)(H,65,77)(H,66,74)(H,67,72)(H,68,78)(H,69,73)
InChIKey=GAWXLRUZZFSQON-UHFFFAOYNA-N
1131.371
1130.483013278
Exogenous
Solid
HMDB15601
CHEMBL2103975
64425
<p>Venkata Raghavendra Palle, Maheedhara Reddy Challa, “<span class="caps">PROCESS</span> <span class="caps">FOR</span> <span class="caps">PREPARING</span> <span class="caps">VAPREOTIDE</span>.” U.S. Patent US20070111930, issued May 17, 2007.</p>